CD161 encoded by KLRB1 was recently identified as a novel immune checkpoint molecule, and blocking the CD161-CLEC2D pathway strongly enhanced T cell killing against tumor cells and reduced T cell exhaustion [23]. Here, CLEC2D is linked to neoplasm.